Increased production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 by inflamed mucosa in inflammatory bowel disease

Louis, Édouard; Ribbens, Clio; Godon, A.; Franchimont, Denis; Groote, D. De; Hardy, N; Boniver, Jacques; Bélaïche, Jacques; Malaise, Michel

doi:10.1046/j.1365-2249.2000.01227.x

Cited by 136 publications

(111 citation statements)

References 31 publications

Supporting

Mentioning

101

Contrasting

Unclassified

Order By: Relevance

“…Alterations of MMPs activity depending on the degree of disease exacerbation have been observed in animal models with induced bowel inflammation [11,12]. Elevated concentrations of MMPs have also been noted in biopsy specimens collected from inflamed fragments of the alimentary tract [1,2,13,14]. Despite these reports, there are only a few accounts concerning the possibility of the measurement of MMPs in samples other than tissue.…”

Section: Discussionmentioning

confidence: 99%

Metalloproteinase-3 and -9 as Novel Markers in the Evaluation of Ulcerative Colitis Activity in Children

Kofla-Dłubacz¹,

Matusiewicz²,

Krzesiek³

et al. 2014

Adv Clin Exp Med

View full text Add to dashboard Cite

Objectives. The enhanced activity of matrix endopeptidases (MMPs) involved in the degradation of connective tissue has been noted in tissue samples from the digestive tract in inflammatory bowel disease (IBD), however sera concentrations of MMPs, a potential tool for diagnostic tests in IBD patients, have not been established so far. The goal of the studies was to evaluate the concentrations of MMP-3 and MMP-9, in the sera of children suffering from ulcerative colitis (UC) in relation to disease activity. Material and Methods. The study was comprised of 31 children with UC (aged 3-18 years) and 37 children in the control group (aged 1-18 years). Disease activity was estimated using the Truelove-Witts scale. MMP-3 and -9 concentrations were determined using ELISA tests. Results. Median MMP-3 concentrations were 18.4 ng/mL (95% CI: 12.5-24.3) for moderate and severe, 4.35 ng/mL (95% CI: 2.5-7.8) for the mild form of UC and 1.8 ng/mL (95% CI: 1.2-2.5) for the control group. Median MMP-9 concentrations were 18.0 ng/mL (95% CI: 2.83-36.6) for moderate and severe, 1.55 ng/mL (95% CI: 0.4-3.0) for the mild form of UC and 1.3 ng/mL (95% CI: 0.7-1.96) for the control group. Serum MMP-3 and MMP-9 concentrations in the moderate group were higher than those in the mild and control groups (p < 0.001). MMP-3 concentrations in the mild group also differed from those in the control group (p < 0.001). Among the parameters studied (MMP-3, MMP-9, CRP and ESR), MMP-3 had the highest discriminative value (AUC = 0.9, p < 0.001, sensitivity = 71%, specificity = 92%) in distinguishing patients with UC from healthy individuals. Conclusions. Elevation of MMP-3 and MMP-9 concentrations along with the disease activity suggests the possibility of their application in the evaluation of the clinical activity of UC (Adv Clin Exp Med 2014, 23, 1, 103-110).

show abstract

Section: Discussionmentioning

confidence: 99%

Metalloproteinase-3 and -9 as Novel Markers in the Evaluation of Ulcerative Colitis Activity in Children

Kofla-Dłubacz¹,

Matusiewicz²,

Krzesiek³

et al. 2014

Adv Clin Exp Med

View full text Add to dashboard Cite

show abstract

“…The gelatinases A (MMP-2) and B (MMP-9) have been shown to be highly upregulated in small as well as large intestinal inflammation in mice and men [11][12][13][14][15][16]. We have recently reported that selective blockage of gelatinases by the synthetic compound RO28-2653 was effectively ameliorating acute ileitis [17] and colitis [18].…”

Section: Discussionmentioning

confidence: 99%

“…In experimental models of Th1-type inflammation (e.g. rheumatoid arthritis, atherosclerosis and colitis) [7][8][9][10] as well as in humans with inflammatory bowel diseases (IBDs) such as ulcerative colitis and Crohn's disease [11][12][13][14][15][16], levels of gelatinases A (MMP-2) and B (MMP-9) are increased in inflamed tissue sites.…”

Section: Introductionmentioning

confidence: 99%

The distinct roles of MMP-2 and MMP-9 in acute DSS colitis

Heimesaat¹,

Dunay²,

Fuchs³

et al. 2011

European Journal of Microbiology and Immunology

View full text Add to dashboard Cite

Expression of gelatinases A and B, also referred to matrixmetalloproteinases (MMP)-2 and -9, respectively, is increased in inflamed tissues of experimental intestinal inflammation and humans with inflammatory bowel disease (IBDs). Given that we recently reported that treatment with the selective gelatinase inhibitor RO28-2653 ameliorates acute dextrane sulfate sodium (DSS) colitis, we asked whether gelatinase A or B expression is pivotal in mediating large intestinal inflammation. Results from our study reveal that symptoms of acute DSS colitis as well as histopathological colonic changes were ameliorated in MMP-2-, but not MMP-9-deficient mice, and were paralleled by a diminished influx of immune cells. In MMP-2-deficient mice, we observed lower expression of pro-inflammatory cytokines including interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), and IL-6 in colonic biopsies and less overgrowth of the colonic lumen by potentially pro-inflammatory enterobacteria from the commensal gut microbiota. We conclude that rather MMP-2 than MMP-9 is causative for the establishment of DSS colitis in mice. The discrepancy of these data to prior reports might be due to substantial differences in the intestinal microbiota composition of the mice bred at different animal facilities impacting susceptibility to inflammatory stimuli. Consequently, a detailed survey of the gut microbiota should be implemented in immunological/inflammatory studies in the future in order to allow comparison of data from different facilities.

show abstract

“…23 TIMP1 is one of the intrinsic inhibitors of MMPs, a key effector of T cell-mediated tissue injury. [24][25][26] The transport of fatty acids from the plasma membrane to cellular organelles is believed to be performed by the FABP family. As FABP is consumed during inflammation of its producing organs, 27,28 such as liver, heart and intestinal epithelium, L-FABP in inflamed UC mucosa may decrease by a similar mechanism.…”

Section: 21mentioning

confidence: 99%

Inflammatory gene signature in ulcerative colitis with cDNA macroarray analysis

Okahara

Arimura

Yabana³

et al. 2005

Aliment Pharmacol Ther

View full text Add to dashboard Cite

SUMMARYBackground: Most array analyses of ulcerative colitis have focused on identifying susceptibility genes for ulcerative colitis. Aim: To clarify the changes in gene expression during inflammation in ulcerative colitis colon mucosa using cDNA macroarray. Methods: From 23 ulcerative colitis patients, 16 each of inflamed and non-inflamed specimens (total 32 samples for individual analysis) were obtained by colonoscopic biopsy. Eighteen of the 32 samples, used for pairwise analysis, consisted of nine sample pairs, each pair being from the same patient. We examined expression profiles of approximately 1300 genes with cDNA macroarray.

show abstract

Increased production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 by inflamed mucosa in inflammatory bowel disease

Cited by 136 publications

References 31 publications

Metalloproteinase-3 and -9 as Novel Markers in the Evaluation of Ulcerative Colitis Activity in Children

Metalloproteinase-3 and -9 as Novel Markers in the Evaluation of Ulcerative Colitis Activity in Children

The distinct roles of MMP-2 and MMP-9 in acute DSS colitis

Inflammatory gene signature in ulcerative colitis with cDNA macroarray analysis

Contact Info

Product

Resources

About